SK86997A3 - Imides/amides as immunotherapeutic agents, pharmaceutical composition and their use for reducing level of tnf-alpha - Google Patents

Imides/amides as immunotherapeutic agents, pharmaceutical composition and their use for reducing level of tnf-alpha Download PDF

Info

Publication number
SK86997A3
SK86997A3 SK869-97A SK86997A SK86997A3 SK 86997 A3 SK86997 A3 SK 86997A3 SK 86997 A SK86997 A SK 86997A SK 86997 A3 SK86997 A3 SK 86997A3
Authority
SK
Slovakia
Prior art keywords
group
substituted
carbon atoms
tnf
alkoxy
Prior art date
Application number
SK869-97A
Other languages
English (en)
Slovak (sk)
Inventor
George Muller
Mary Shire
David I Stirling
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of SK86997A3 publication Critical patent/SK86997A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK869-97A 1994-12-30 1995-11-20 Imides/amides as immunotherapeutic agents, pharmaceutical composition and their use for reducing level of tnf-alpha SK86997A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36666794A 1994-12-30 1994-12-30
PCT/US1995/015119 WO1996020705A1 (fr) 1994-12-30 1995-11-20 IMIDES/AMIDES IMMUNOTHERAPEUTIQUES ET LEUR UTILISATION POUR REDUIRE LE NIVEAU DU FACTEUR α DE NECROSE DE TUMEURS

Publications (1)

Publication Number Publication Date
SK86997A3 true SK86997A3 (en) 1998-01-14

Family

ID=23443993

Family Applications (1)

Application Number Title Priority Date Filing Date
SK869-97A SK86997A3 (en) 1994-12-30 1995-11-20 Imides/amides as immunotherapeutic agents, pharmaceutical composition and their use for reducing level of tnf-alpha

Country Status (18)

Country Link
EP (1) EP0797437B1 (fr)
JP (1) JPH10511678A (fr)
AT (1) ATE200621T1 (fr)
AU (1) AU696817B2 (fr)
CA (1) CA2208672C (fr)
CZ (1) CZ290372B6 (fr)
DE (1) DE69520750T2 (fr)
DK (1) DK0797437T3 (fr)
ES (1) ES2155537T3 (fr)
FI (1) FI972708L (fr)
GR (1) GR3036131T3 (fr)
HU (1) HU226558B1 (fr)
NZ (1) NZ296925A (fr)
PL (1) PL185101B1 (fr)
PT (1) PT797437E (fr)
RU (1) RU2164514C2 (fr)
SK (1) SK86997A3 (fr)
WO (1) WO1996020705A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658940A (en) * 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
DE69700616T2 (de) * 1996-07-02 2000-03-16 Nisshin Flour Milling Co., Ltd. Imid derivate
ES2262184T3 (es) * 1996-08-05 2006-11-16 Myriad Genetics, Inc. Utilizacion de mimeticos de hojas beta como inhibidores de proteasa y de kinasa o como inhibidores de factores de transcripcion.
EP1661566A3 (fr) * 1996-08-05 2008-04-16 Myriad Genetics, Inc. Utilisation de mimétiques de feuillets beta comme inhibiteurs de protéase et de kinase ou comme inhibiteurs de facteurs de transcription
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
CA2438641A1 (fr) 2001-02-15 2002-08-22 King Pharmaceuticals, Inc. Compositions pharmaceutiques stabilisees, compositions d'hormone de thyroide et technique de preparation
CA2439410C (fr) 2001-02-27 2011-09-06 William D. Figg Analogues de thalidomide utilises comme inhibiteurs potentiels de l'angiogenese
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
EP1663223B1 (fr) 2003-09-17 2014-01-01 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Analogues du thalidomide comme inhibiteurs de tnf-alpha
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4467097A (en) * 1982-09-29 1984-08-21 General Electric Company Method for making aromatic bis(etherimide)s
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines

Also Published As

Publication number Publication date
FI972708A7 (fi) 1997-08-29
PL185101B1 (pl) 2003-02-28
HUT77978A (hu) 1999-01-28
CZ203597A3 (en) 1997-11-12
DK0797437T3 (da) 2001-06-05
ES2155537T3 (es) 2001-05-16
GR3036131T3 (en) 2001-09-28
EP0797437A1 (fr) 1997-10-01
CZ290372B6 (cs) 2002-07-17
CA2208672C (fr) 2008-02-12
AU696817B2 (en) 1998-09-17
DE69520750D1 (de) 2001-05-23
FI972708L (fi) 1997-08-29
RU2164514C2 (ru) 2001-03-27
HU226558B1 (en) 2009-03-30
FI972708A0 (fi) 1997-06-23
NZ296925A (en) 1998-06-26
AU4166796A (en) 1996-07-24
PT797437E (pt) 2001-07-31
ATE200621T1 (de) 2001-05-15
CA2208672A1 (fr) 1996-07-11
WO1996020705A1 (fr) 1996-07-11
EP0797437B1 (fr) 2001-04-18
DE69520750T2 (de) 2001-09-13
JPH10511678A (ja) 1998-11-10
PL321071A1 (en) 1997-11-24

Similar Documents

Publication Publication Date Title
EP0800505B1 (fr) Arylamides immunotherapeutiques nouveaux
US6844359B2 (en) Substituted imides
US5658940A (en) Succinimide and maleimide cytokine inhibitors
US5728845A (en) Immunotherapeutic nitriles
AU735540B2 (en) Novel immunotherapeutic imides/amides
SK13642000A3 (sk) 2-(2,6-dioxopiperidin-3-yl)izoindolínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
SK86997A3 (en) Imides/amides as immunotherapeutic agents, pharmaceutical composition and their use for reducing level of tnf-alpha
KR100496308B1 (ko) 면역요법용 이미드/아미드 및 ＴＮＦα의 레벨을감소시키는 이의 용도
CZ192999A3 (cs) Imunoterapeutické imidy/amidy jako PDE a TNF inhibitory, farmaceutická kompozice obsahující tyto imidy/amidy, způsob redukce hladin TNFalfa a způsob inhibice fosfodiesterázy u savců